PubMed · 2003 · 21 citations · 12 references
MedicineClinical SciencesPharmacotherapyMusculoskeletal MedicinePain ManagementRheumatologyAutoimmune Rheumatic DiseasesInflammatory ArthritisJoint DiseaseRheumatoid ArthritisCollagen Drug Delivery SystemsDisease Activity MeasurementOpen-label TrialsRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis TherapyStiffnessSubcutaneous Drug AdministrationSubcutaneous Medication Administration
OBJECTIVE: To determine the efficacy, tolerance and safety of subcutaneous injections of porcine type I collagen-polyvinylpyrrolidone (PVP) in patients with rheumatoid arthritis (RA). METHODS: Eleven patients with active RA on stable therapy with methotrexate (MTX) were enrolled in a 3 month prospective and longitudinal study. Patients were treated weekly with subcutaneous injections of 0.2 ml of collagen-PVP (1.7 mg of collagen) in the 8 most painful joints. The primary endpoints included the Ritchie index (RI), swollen joint count, disease activity score (DAS), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). The secondary endpoints included morning stiffness, pain intensity on a visual analog scale (VAS), and the Spanish-Health Assessment Questionnaire Disability Index (HAQ-DI). Improvement was determined using American College of Rheumatology (ACR) response criteria. RESULTS: Collagen-PVP was safe and well-tolerated and there were no adverse events. Patients had a statistically significant improvement (p < 0.05) in basal versus 3 month's treatment in morning stiffness (Delta -32.3, -68.6%), RI (Delta -10.2, -46.4%), swollen joint count (Delta -10.7, -71.8%), VAS (Delta -39.9, -63.8%), HAQ-DI (Delta -0.5, -48.5%), DAS (Delta -1.35, -70.5%) and ACR20, 50, and 70 (80.0%; 60.0% and 20.0% respectively). We found no differences in serologic or hematologic variables. CONCLUSION: Collagen-PVP was a safe and well-tolerated drug for the short term treatment of RA. The combination of collagen-PVP plus MTX was more efficacious than MTX alone. However, double-blind placebo-controlled phase II and III clinical trials are necessary to determine whether this drug could be useful in the longterm treatment of RA.
12
Revised criteria for the classification of rheumatoid arthritis.
PubMed · 1989 · 902 citations
Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis
David E. Trentham, Roselynn Dynesius‐Trentham, E. John Orav et al. · Science · 1993 · 631 citations
David T. Felson, Jennifer J. Anderson, M. Lange et al. · Arthritis & Rheumatism · 1998 · 192 citations